JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

600513

CNE000001DP6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
8.27 ^CNY	-0.12%		-0.12%	-25.76%

05/06	China Approves Lianhuan Pharma's Prostate Cancer Tablets	MT
29/04	Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Elects Wang Guangji Director as Director

August 22, 2018

Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that at the special shareholders meeting held on August 22, 2018 approved the proposal of electing Wang Guangji Director of 7th Directorate.

Latest news about Jiangsu Lianhuan Pharmaceutical Co., Ltd.

China Approves Lianhuan Pharma's Prostate Cancer Tablets	05/06	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Lianhuan Pharma Obtains China Registration Approval for Antihistamine	09/04	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03	CI
Lianhuan Pharma's Production Lines Pass GMP Inspection	07/11	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Jiangsu Lianhuan Pharma Passes GMP Compliance Inspection	19/23/19	MT
MFM KOREA Co., Ltd. announced that it expects to receive KRW 23.99999924 billion in funding from Jiangsu Lianhuan Pharmaceutical Co., Ltd. and other investors	06/23/06	CI
Jiangsu Lianhuan Pharma Gets Nod to Market Ingredient For Drug Against Addison’s Disease	15/23/15	MT
Jiangsu Lianhuan Pharma Plans Listing Unit on ‘New Third Board’	12/23/12	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Foyou Pharma Passes Drug GMP Compliance Inspection	14/23/14	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Jiangsu Lianhuan Pharma to Raise 450 Million Yuan From Bond Sale	09/23/09	MT
Lianhuan Pharma Gets Nod for Erectile Dysfunction Drug	06/23/06	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI
Jiangsu Lianhuan Pharmaceutical Gets Nod to Market Antihistamine Ingredient in China	10/23/10	MT
Lianhuan Pharma Gets Nod for Anti-Allergy Drug Registration	09/23/09	MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	21/22/21	CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/22/24	CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	27/22/27	CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	24/21/24	CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	29/21/29	CI

Chart Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Duration

Period

Chart Jiangsu Lianhuan Pharmaceutical Co., Ltd.

More charts

Jiangsu Lianhuan Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, production and sales of chemical medicines. The Company's products are mainly applied as urinary system medicines, antihistamines and cardiovascular medicines. The Company's products include Epristeride Tablets, Ebastine Tablets, Felodipine Tablets, Felodipine Sustained Release Capsules, Simvastatin Tablets, Lumbrokinase Capsulesand and Balofloxacin Tablets. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.	-25.76%	325M
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B